Aug 25, 2014 8:05 am EDT Heat Biologics, Inc. Closes on Up to $7.5 Million Secured Term Loan Facility
Aug 04, 2014 8:05 am EDT Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies
May 30, 2014 8:05 am EDT Heat Biologics Receives Green Light to Expand Enrollment of Its Phase 1/2 Study of HS-410 in Bladder Cancer Based on Encouraging Preliminary Safety Results
Apr 09, 2014 12:00 pm EDT Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research
Apr 01, 2014 7:35 am EDT Heat Biologics, Inc. Reports 2013 Fourth Quarter and Full Year Financial Results
Mar 26, 2014 4:15 pm EDT Heat Biologics, Inc. to Present at the MaidStone Life Sciences Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 27, 2014
Mar 19, 2014 8:00 am EDT Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
Mar 10, 2014 8:05 am EDT Heat Biologics, Inc. Presents Preclinical Data From Comparative Combination Cancer Immunotherapy Research Study at Keystone Symposia on Immune Evolution in Cancer